Oncology 04/2023 Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma Clinical Cancer Research Graviton Love0
NASH 09/2022 FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models Scientific Reports Graviton Love12
Oncology 07/2022 Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer Nature Communications Graviton Love0
Oncology 01/2022 Therapeutic efficacy of FASN inhibition in preclinical models of HCC Hepatology Graviton Love9
NASH 07/2021 TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial Gastroenterology Graviton Love9
Oncology 04/2021 First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors EClinicalMedicine Graviton Love9
NASH 07/2020 Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities Hepatology 2020 Graviton Love9
Oncology 02/2017 Fatty Acid Synthase – Modern Tumor Cell Biology Insights into a Classical Oncology Target Pharmacology and Therapeutics natalia Love8
Oncology 12/2016 FASN inhibition and taxane treatment combine to enhance anti-tumor efficacy in diverse xenograft tumor models through disruption of tubulin palmitoylation and microtubule organization and FASN inhibition-mediated effects on oncogenic signaling and gene expression EBioMedicine natalia Love6
Oncology 08/2016 DeNovo Palmitate Synthesis Supports Oncogenic Signaling Through Diverse Mechanisms: Implications for FASN-Targeted Therapeutics Journal of Cell Signaling natalia Love6